A study found that renal arteriosclerosis develops 2 decades earlier in patients with lupus nephritis compared with healthy age-matched controls.
GlaxoSmithKline announced positive results from the phase 3 BLISS-LN trial of belimumab for the treatment of active lupus nephritis in adult patients.
The FDA has granted Fast Track designation for itolizumab (EQ001; Equillium) for the treatment of lupus nephritis.
Voclosporin was found to be superior to standard-of-care treatment in patients with lupus nephritis, according to data from the phase 3 AURORA trial.
This study reports the long-term renal outcomes of kidney biopsies performed at prespecified intervals to determine the safety and accuracy of tapering of maintenance immunosuppression.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to obinutuzumab (Genentech), a CD20-directed cytolytic antibody, for the treatment of adults with lupus nephritis. The designation was based on data from the phase 2 NOBILITY study that compared the efficacy and safety of obinutuzumab, in combination with mycophenolate mofetil (MMF) or mycophenolic acid…
In a small study, patients with lupus nephritis who underwent renal transplantation had 5-year graft and patient survival rates of 76.3% and 92.5%, respectively.
Investigators examined racial/ethnic differences in manifestations of lupus and in the timing and risk of developing severe manifestations.
Deaths among blacks occur sooner after diagnosis and at younger age compared with whites
More adverse childhood experiences associated with depression, poor overall health for those with SLE